SAN DIEGO, Oct. 27 /PRNewswire/ -- BioAtom Inc. (private) announced today that it will present at the 3rd annual BIOCOM Investor Conference on Tuesday, October 28, 2008 at 2:30 PM PDT (5:30 PM EDT) at the Hyatt Regency La Jolla in San Diego, California.
Myron Karasik, M.B.A., C.M.C., Director of Finance, will present an overview of Medical Division of BioAtom Inc. of Costa Mesa, CA, dedicated to development and commercialization of Neutron Cancer Diagnostics. Its ONCOSENSOR(TM), a nanotechnology probe, will undergo in vivo evaluation at Center for Functional Onco Imaging, UC Irvine, in collaboration with Radiation Oncology Group, Long Beach Memorial Hospital.
From Bomb Detector to Cancer Diagnostic Probe. Malignant tumors are chemically different from normal tissue. ONCOSENZOR(TM) can non-invasively detect in vitro chemical differences as small as 1 atom/molecule. Its core technology was developed under US Army contracts for non-intrusive detectors of bioagents and explosives in a previous company (no longer in existence), by co-founders of BioAtom, at a cost to shareholders of over $40 million.
Our mission is to provide an early warning, walk-in, painless (non-invasive) and "instant" (online) cancer diagnosis aid that is a quantum leap ahead of competing firms. Operating in tandem with any one of the imaging probes, we hope to ultimately achieve needle-less biopsy. The method has the potential for forewarning of stroke, Alzheimer, and cardiovascular diseases.
Marketing of ONCOSENZOR(TM) to animal clinics, a $13 Billion/year market, does not require FDA approval.
Anna Radovic, Ph.D., 36, President and Chief Scientific Officer, an
international cancer researcher and co-patentee, was first to irradiate DNA
by neutrons. Christian Druey, B.E.E., 38, has been instrumental in
commercialization of medical imaging and explosive detection devices.
Bogdan Maglich, Ph.D., CTO and Chairman, the inventor of the core
technology, has been
|SOURCE BioAtom Inc.|
Copyright©2008 PR Newswire.
All rights reserved